UNSPSC 51293702: Nomifensine

This classification denotes an antidepressant agent with the molecular formula C16H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1LGS5JRP31, chemically known as 1,2,3,4-tetrahydro-2-methyl-4-phenyl-8-isoquino* but generally known as nomifensine, which bears US NIH Compound Identifier 4528. European Medicines Agency schedules Nomifensine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09347MIG.

UNSPSC 51293702 Nomifensine is a Commodity code, but the recent state and local opportunities posted under this designation show a fundamental mismatch: the code nominally covers nomifensine, an antidepressant medication, yet the solicitations actually being issued are for naloxone (opioid reversal), generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription program services. State and local governments are using this code primarily to procure emergency-response medications, generic pharmaceutical supply agreements, and pharmacy benefit management infrastructure. The issuing bodies reflect the breadth of public health procurement: county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing alliances administering on behalf of state and local government members (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and participating jurisdictions). The work ranges from tactical purchases of specific medications for community health initiatives to strategic procurement of generic pharmaceutical catalogs serving entire state health systems.

Recent opportunities span Florida, Texas, and the Upper Midwest. Seminole County's IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Texas HHS issued an RFI (HHS0017013, April 3, 2026) to explore direct-to-manufacturer prescription contracting models and pharmacy benefit program restructuring. The Minnesota Multistate Cooperative Purchasing Alliance released an RFP (S1070000015802, due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with products effective July 1, 2026, requiring vendor compliance with cGMP, DSCSA, and NDC-based pricing submissions through authorized wholesalers AmerisourceBergen, Cardinal Health, and Morris & Dickson. The code shows active procurement volume in emergency medicine and generic pharmaceutical distribution, though the disconnect between the code's nominal scope and actual purchasing suggests a data-classification issue rather than genuine nomifensine-specific demand.